Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by stockbuphoonon Feb 16, 2022 1:05pm
175 Views
Post# 34434398

RE:RE:RE:Repays its Secured Debt Ending its Creditor Relationship

RE:RE:RE:Repays its Secured Debt Ending its Creditor Relationship

When a company that has relatively cheap financing for a pre-revenue company and decides to pay a loan back, they are signalling that they cannot use the money for anything valuable like a clinical trial or majority shareholder/ debt holder (same controlling Thomson family behind both companies) want to create perception in market that they have nothing, this is what they do which is not in best interests of minority shareholders (more retailer oppression). How does this help the company move forward? They need tons of money for any clinical trial. This is my opinion. Open to other thoughts of what they may be doing with this move but it seems like Thomson are taking back their loan to sink company and take private as the seeming orchestration of press releases.

They have taken advanced 4050 indications off clinical trial lists last May (Alstrom and MetSyn apparently before that time), said they will review pk data for another potential indication by end of 2021 and announce at end of 2021 that they'll have analysis by mid 2022 (18 months from beginning of trial). So, they knew that 4050 for 5 indications that previously displayed good results that they would not go forward with them within 5 months of trial start but they need another 13 months to see if there is another potential indication? Now, Thomson grabs the loan money he lent with board of director approval influenced very heavily by Thomson majority owner. Not sure what other theories you guys have but this looks bleak. Yes, SALP gave IP back but they have delivered another dagger to their company to downplay any value so they can pick up pieces for nothing in the end. If 4050 really was worth something, Boehringher may buy it out but they didn't have to announce this transaction before due diligence. 

It's one theory but the difference in todays world between conspiracy theory and truth is usually about 3-6 months.

aldo451 wrote: Exactly my thoughts 33, but no worries, they will put a negative spin on it...it's all part of the evil  plan. 

 

<< Previous
Bullboard Posts
Next >>